Upadacitinib for refractory CD safe, effective in real-world use
In a real-world cohort of patients with highly refractory Crohn’s disease (CD), upadacitinib treatment prompted clinical response in most and steroid-free clinical remission in half, while having an acceptable safety profile.
Upadacitinib for refractory CD safe, effective in real-world use
13 Mar 2025
